News & Press Releases

Nov

13

2024

PULMATRIX AND CULLGEN ANNOUNCE PROPOSED MERGER

FRAMINGHAM and SAN DIEGO, November 13, 2024 Pulmatrix, Inc. (“Pulmatrix”) (Nasdaq: PULM), a clinical-stage biopharmaceutical company, today announced a merger agreement with Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases. Cullgen utilizes its proprietary technology platform, uSMITE™, featuring novel E3 ligands, to build the next generation of targeted protein degraders and degrader-antibody conjugates (“DACs”).


Oct

8

2024

CULLGEN ANNOUNCES CHINESE NMPA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CG009301, A HIGHLY SELECTIVE GSPT1 DEGRADER

SAN DIEGO, October 8, 2024 Cullgen Inc., a leading biotechnology company developing targeted protein degraders based on its proprietary uSMITE™ platform technology, today announced that the Chinese National Medical Products Administration (NMPA) has allowed the Investigational New Drug (IND) application for CG009301, a highly selective GSPT1 degrader for the treatment of relapsed or refractory hematological malignancies (including but not limited to AML, ALL, and high-risk MDS). Cullgen will soon initiate the Phase I clinical trial of CG009301 in humans in China.


Jan

16

2024

CULLGEN ANNOUNCES ADDITIONS TO BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD

SAN DIEGO, January 16, 2024 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced the addition of Xiaogang Pan, PhD to its Board of Directors, and Ian Storer, PhD to its Scientific Advisory Board.


Oct

15

2023

CULLGEN AND ASTELLAS HONORED WITH 2023 LES DEALS OF DISTINCTION AWARD

SAN DIEGO, October 15, 2023 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has earned a Deals of Distinction award from the Licensing Executives Society (LES) for its Collaboration, Option and License Agreement with Astellas announced earlier in 2023.


July

27

2023

CULLGEN ANNOUNCES FIRST-IN-HUMAN DOSE IN PHASE I/II TRIAL OF CG001419, A FIRST-IN-CLASS TRK PROTEIN DEGRADER FOR TREATMENT OF CANCER PATIENTS

CG001419 is Cullgen’s first protein degrader to enter clinical development

SAN DIEGO and SHANGHAI, July 27, 2023 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has initiated dosing with its orally bioavailable pan-TRK degrader, CG001419, in a Phase I/II clinical trial for patients with solid tumors.


June

14

2023

ASTELLAS AND CULLGEN ENTER INTO STRATEGIC COLLABORATION AND OPTION AGREEMENT TO ADVANCE INNOVATIVE TARGETED PROTEIN DEGRADERS

TOKYO and SAN DIEGO, June 14, 2023 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Cullgen Inc. (President and CEO: Ying Luo, Ph.D., “Cullgen”) today announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.


May

08

2023

CULLGEN RAISES $40 MILLION IN NEW FINANCING LED BY ASTRAZENECA-CICC FUND

SAN DIEGO and SHANGHAI, May 08, 2023 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITETM platform of targeted protein degradation technology, today announced that it has raised $40 million in new financing.


Aug

09

2022

CULLGEN ANNOUNCES CHINESE NMPA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF TRK DEGRADER TO BEGIN CLINICAL TRIALS

SAN DIEGO, California, USA, August 9, 2022 Cullgen Inc., a leading biotechnology company developing targeted protein degraders based on its proprietary uSMITE™ platform technology, today announced that the Chinese National Medical Products Administration (NMPA) has allowed the Investigational New Drug (IND) application for CG001419, a TRK degrader for the treatment of solid tumors. CG001419 is a first-in-class, selective, potent oral targeted protein degrader for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive cancers, which have been identified in numerous solid tumors including non-small cell lung, breast, and pancreatic cancers.


Sept

23

2021

NATURE REVIEWS CANCER SELECTS PUBLICATION BY CULLGEN CO-FOUNDERS FOR INCLUSION IN 20TH ANNIVERSARY ISSUE

SAN DIEGO, California, USA, September 23, 2021 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, is honored that the article co-authored by Cullgen founders Dr. Jian Jin and Dr. Yue Xiong entitled “Advancing Targeted Protein Degradation for Cancer Therapy”, has been included in the 20th Anniversary Issue of the prestigious journal, Nature Reviews Cancer.


June

16

2021

CULLGEN ANNOUNCES PROMINENT PUBLICATION BY CULLGEN CO-FOUNDERS JIAN JIN AND YUE XIONG IN NATURE REVIEWS CANCER

SAN DIEGO, California, USA, June 16, 2021 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that Drs. Jian Jin and Yue Xiong, co-founders of Cullgen, have published a review of targeted protein degradation technology as well as a comprehensive summary of degraders in development for the treatment of cancer in the prestigious journal, Nature Reviews Cancer.


June

10

2021

CULLGEN APPOINTS MARK DEEG TO LEAD CLINICAL DEVELOPMENT

SAN DIEGO, California, USA, June 10, 2021 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that Mark Deeg, M.D., Ph.D., has joined the company as Executive Vice President of Clinical Development.


Feb

25

2021

CULLGEN CLOSES $50 MILLION SERIES B INVESTMENT TO ADVANCE TARGETED PROTEIN DEGRADERS AND NOVEL E3 LIGANDS PLATFORM

SAN DIEGO and SHANGHAI, February 25, 2021 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has closed a $50 million Series B financing.


Dec

03

2020

TARGETED PROTEIN DESTRUCTION: ADVANCES IN PROTACS OTHER DEGRADERS

December 3, 2020 Cullgen featured in targeted protein degradation article in Genetic Engineering & Biotechnology News


Oct

15

2020

CULLGEN ANNOUNCES “FEATURED ARTICLE” PUBLICATION OF FIRST IN CLASS TRK PROTEIN DEGRADERS IN JOURNAL OF MEDICINAL CHEMISTRY

October 15, 2020 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.


Apr

06

2020

CULLGEN ANNOUNCES PUBLICATION OF SMALL MOLECULE BRAF PROTEIN DEGRADERS IN JOURNAL OF MEDICINAL CHEMISTRY

April 6, 2020 Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key BRAF mutant proteins has been accepted for publication by the Journal of Medicinal Chemistry.


Dec

10

2019

CULLGEN ANNOUNCES KEY PUBLICATION BY CULLGEN CO-FOUNDER JIAN JIN IN NATURE CHEMICAL BIOLOGY

December 10, 2019 Cullgen Inc., a biotechnology company developing small molecule therapeutics based on targeted protein degradation technology (commonly known as PROTAC), today announced that Dr. Jian Jin, a co-founder of Cullgen, has designed a novel targeted protein degrader that may be able to stop the growth of triple-negative breast cancer, a type of breast cancer for which there are few viable treatment options, according to a study recently published in Nature Chemical Biology entitled “Discovery of a first-in-class EZH2 selective degrader”.


Sept

09

2019

CULLGEN: BOOSTING THE BREADTH OF E3 LIGASES FOR PROTEIN DEGRADATION

September 9, 2019 Cullgen Emerging Company Profile published by BioCentury


Apr

10

2019

CULLGEN RECEIVES $16 MILLION SERIES A INVESTMENT TO ADVANCE PIPELINE OF TARGETED PROTEIN DEGRADERS

April 10, 2019 Series A financing led by two leading global venture capital firms – Sequoia Capital China and HighLight Capital.


July

18

2018

CULLGEN ANNOUNCES EXPANDED SCIENTIFIC ADVISORY BOARD

DELAWARE, July 18, 2018 Cullgen Inc, (“Cullgen” or the “Company), a drug discovery company focused on development of drug candidates using uSMITE™ (ubiquitin mediated small molecule induced target elimination), announced that Dr. Timothy Heffernan and Dr. Michele Pagano have joined the Company’s Scientific Advisory Board (SAB).


July

11

2018

EXECUTIVES OF CULLGEN TO PRESENT AT INTERNATIONAL CONFERENCES

DELAWARE, July 11, 2018 Executives of Cullgen Inc. ("Cullgen") have been invited to present research findings at three international drug discovery conferences in US and China.


Apr

03

2018

CULLGEN ANNOUNCES PUBLICATION BY CO-FOUNDERS IN EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

DELAWARE, April 3, 2018 Cullgen Inc., a biopharmaceutical company focusing on developing new drugs using protein degradation technology today announced that the laboratories of its co-founders, Dr. Jian Jin and Dr. Yue Xiong, have published an article in European Journal of Medicinal Chemistry featuring first-in-class small-molecule degraders of Anaplastic Lymphoma Kinase.


Mar

01

2018

CULLGEN ANNOUNCES SEED FINANCING

TOKYO, March 1, 2018 Cullgen Inc. ("Cullgen") today announced a Seed Financing of up to $15M by GNI Group Ltd. (GNIG) (TOKYO: 2160) to build a new drug discovery platform based on advanced ubiquitin-mediated protein degradation technology.